Ventyx Biosciences Inc Net Assets
Ventyx Biosciences Inc net assets. Based on the latest financial reports, Ventyx Biosciences Inc (VTYX) has net assets worth $191.36 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($211.47 Million) and total liabilities ($20.10 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Ventyx Biosciences Inc net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $191.36 Million |
| % of Total Assets | 90.49% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 23.8 |
Net Assets of Ventyx Biosciences Inc (2019–2024)
Net assets of Ventyx Biosciences Inc from 2019 to 2024. This chart illustrates how Ventyx Biosciences Inc's net assets have evolved over time, based on quarterly financial data. See Ventyx Biosciences Inc (VTYX) net asset quality to measure how much of total assets are equity-financed.
Annual Net Assets for Ventyx Biosciences Inc (2019–2024)
The table below shows the annual net assets of Ventyx Biosciences Inc from 2019 to 2024. For live market cap and overall valuation, see Ventyx Biosciences Inc (VTYX) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $254.04 Million | +4.15% |
| 2023-12-31 | $243.92 Million | -31.07% |
| 2022-12-31 | $353.89 Million | +26.75% |
| 2021-12-31 | $279.20 Million | +1010.81% |
| 2020-12-31 | $-30.65 Million | -642.59% |
| 2019-12-31 | $-4.13 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ventyx Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 54998200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Ventyx Biosciences Inc Net Assets Breakdown (December 2024)
Ventyx Biosciences Inc net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $7.00K | 0.00% |
| Other Comprehensive Income | $157.00K | 0.06% |
| Other Components | $808.19 Million | 318.13% |
| Total Equity | $254.04 Million | 100.00% |
Ventyx Biosciences Inc Competitors by Market Cap
The table below lists competitors of Ventyx Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Under Armour Inc A
NYSE:UAA
|
$1.00 Billion |
|
Auto Partner SA
WAR:APR
|
$1.00 Billion |
|
Dynamic Holding Co. Ltd.
TW:3715
|
$1.01 Billion |
|
Superloop Ltd
AU:SLC
|
$1.01 Billion |
|
Sano Bruno's Enterprises Ltd
TA:SANO1
|
$1.00 Billion |
|
Bio-Thera Solutions Ltd
SHG:688177
|
$1.00 Billion |
|
RITES Limited
NSE:RITES
|
$1.00 Billion |
|
CSSC Offshore & Marine Engineering (Group) Co Ltd
F:GSZ
|
$1.00 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ventyx Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 243,923,000 to 254,045,000, a change of 10,122,000 (4.1%).
- Net loss of 135,122,000 reduced equity.
- New share issuances of 121,649,000 increased equity.
- Other comprehensive income increased equity by 207,000.
- Other factors increased equity by 23,388,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-135.12 Million | -53.19% |
| Share Issuances | $121.65 Million | +47.88% |
| Other Comprehensive Income | $207.00K | +0.08% |
| Other Changes | $23.39 Million | +9.21% |
| Total Change | $- | 4.15% |
Book Value vs Market Value Analysis
This analysis compares Ventyx Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.77x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-2.11 | $14.00 | x |
| 2020-12-31 | $-0.61 | $14.00 | x |
| 2021-12-31 | $5.54 | $14.00 | x |
| 2022-12-31 | $6.74 | $14.00 | x |
| 2023-12-31 | $4.17 | $14.00 | x |
| 2024-12-31 | $3.71 | $14.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ventyx Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -53.19%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.09x
- Recent ROE (-53.19%) is below the historical average (-32.15%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.06 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-25.11 Million |
| 2021 | -30.00% | 0.00% | 0.00x | 1.04x | $-111.67 Million |
| 2022 | -30.64% | 0.00% | 0.00x | 1.05x | $-143.82 Million |
| 2023 | -79.11% | 0.00% | 0.00x | 1.14x | $-217.35 Million |
| 2024 | -53.19% | 0.00% | 0.00x | 1.09x | $-160.53 Million |
Industry Comparison
This section compares Ventyx Biosciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ventyx Biosciences Inc (VTYX) | $191.36 Million | 0.00% | 0.11x | $1.00 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Ventyx Biosciences Inc
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its pipeline includes small molecule therapeutics to treat inflammation across cardiometabolic disorders, neurodegenerative diseases, and inflammatory disorders. The company's portfolio of NLRP3 inhibitors includes VTX958, a sele… Read more